JPH05237141A - Artificial blood vessel and its production - Google Patents
Artificial blood vessel and its productionInfo
- Publication number
- JPH05237141A JPH05237141A JP4076261A JP7626192A JPH05237141A JP H05237141 A JPH05237141 A JP H05237141A JP 4076261 A JP4076261 A JP 4076261A JP 7626192 A JP7626192 A JP 7626192A JP H05237141 A JPH05237141 A JP H05237141A
- Authority
- JP
- Japan
- Prior art keywords
- blood vessel
- artificial blood
- ptfe
- fine fibrous
- thrombus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 112
- 239000002473 artificial blood Substances 0.000 title claims abstract description 102
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 239000000835 fiber Substances 0.000 claims abstract description 35
- 239000011347 resin Substances 0.000 claims abstract description 10
- 229920005989 resin Polymers 0.000 claims abstract description 10
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000001339 alkali metal compounds Chemical class 0.000 claims description 4
- URXNVXOMQQCBHS-UHFFFAOYSA-N naphthalene;sodium Chemical compound [Na].C1=CC=CC2=CC=CC=C21 URXNVXOMQQCBHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 claims description 3
- QXOPMVCCPTYJPU-UHFFFAOYSA-N anthracene;sodium Chemical compound [Na].C1=CC=CC2=CC3=CC=CC=C3C=C21 QXOPMVCCPTYJPU-UHFFFAOYSA-N 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 1
- QOSATHPSBFQAML-UHFFFAOYSA-N hydrogen peroxide;hydrate Chemical compound O.OO QOSATHPSBFQAML-UHFFFAOYSA-N 0.000 claims 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 abstract description 73
- 239000004810 polytetrafluoroethylene Substances 0.000 abstract description 73
- 230000002785 anti-thrombosis Effects 0.000 abstract description 15
- 230000017531 blood circulation Effects 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 10
- 238000005520 cutting process Methods 0.000 abstract description 7
- 208000007536 Thrombosis Diseases 0.000 description 49
- 239000012528 membrane Substances 0.000 description 47
- 238000000034 method Methods 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 17
- 238000002054 transplantation Methods 0.000 description 14
- 238000010438 heat treatment Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 230000001732 thrombotic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 239000001294 propane Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940083342 drysol Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000010687 lubricating oil Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PYVHTIWHNXTVPF-UHFFFAOYSA-N F.F.F.F.C=C Chemical group F.F.F.F.C=C PYVHTIWHNXTVPF-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、生体組織適合性に優れ
たポリテトラフルオロエチレン製の人工血管およびその
製造方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a polytetrafluoroethylene artificial blood vessel excellent in biocompatibility and a method for producing the same.
【0002】[0002]
【従来の技術】人工血管は、生体血管の病変部位の欠損
部を補填する置換移植、病変部位を迂回して血行を維持
するためのバイパス移植、あるいは動脈と静脈との短絡
などの血液導管などとして使用されている。従来、人工
血管の材料としては、編組構造を有するポリエステル繊
維編物や織物、あるいは微細多孔質構造を有する延伸ポ
リテトラフルオロエチレン(以下、PTFEと略記)チ
ューブなどが用いられてきた。2. Description of the Related Art Artificial blood vessels are replacement transplants for filling a defect in a lesion site of a living blood vessel, bypass transplants for bypassing the lesion site to maintain blood circulation, or blood conduits such as short circuits between arteries and veins. Is used as. Conventionally, as a material for an artificial blood vessel, a polyester fiber knitted fabric or a woven fabric having a braided structure, or an expanded polytetrafluoroethylene (hereinafter abbreviated as PTFE) tube having a fine porous structure has been used.
【0003】これらの中でも、延伸PTFEチューブ
(管状四弗化エチレン樹脂多孔質体)は、PTFEを延
伸した後焼成したものであり、編組したものではない
が、繊維(フィブリル)と該繊維によって互いに連結さ
れた結節(ノード)により微細な多孔質構造が形成され
ており、この多孔質構造が生体適合性に優れ、しかもP
TFE素材自体が抗血栓性に優れていることから、主と
して小口径動脈や大口径静脈などの領域における人工血
管として実用化されてきた。Among these, the expanded PTFE tube (tubular tetrafluoride ethylene resin porous body) is a product obtained by expanding PTFE and then firing it, and although it is not braided, it is made of fibers (fibrils) and the fibers. A fine porous structure is formed by the connected nodes, and this porous structure has excellent biocompatibility and P
Since the TFE material itself has excellent antithrombotic properties, it has been put to practical use mainly as an artificial blood vessel in the areas of small-diameter arteries and large-diameter veins.
【0004】人工血管には、初期開存率および長期開存
率の高いことが求められる。開存率には、種々の影響因
子が関与するが、その中でも材料の抗血栓性がきわめて
重要な影響を及ぼす。しかしながら、延伸PTFEチュ
ーブでも抗血栓性が必ずしも十分であるとはいえず、特
に内径6mm以下の小口径の人工血管では、十分な長期
開存率は得られていない。An artificial blood vessel is required to have a high initial patency rate and a long-term patency rate. Various factors are involved in the patency rate, and among them, the antithrombogenicity of the material has a very important influence. However, it cannot be said that the expanded PTFE tube also has sufficient antithrombotic properties, and in particular, a sufficient long-term patency rate has not been obtained with a small-diameter artificial blood vessel having an inner diameter of 6 mm or less.
【0005】人工血管の抗血栓性を改善する方法とし
て、(1)材料自体の抗血栓性を向上させる方法、
(2)人工血管を移植後に、生体組織を誘導し、内膜形
成を起こすことによって抗血栓性を付与する方法、など
が検討されている。しかしながら、(1)の方法におい
ては、相分離構造等の抗血栓性高分子材料や、抗血栓剤
固定化材料の開発が検討されているが、移植後長期にわ
たって良好な抗血栓性を示す材料は得られていない。
(2)の方法においては、移植後の内膜形成を促進する
ために、血管外部からの生体組織や毛細血管の侵入を促
進する方法についての検討がなされているのが現状であ
る。As a method for improving the antithrombotic property of the artificial blood vessel, (1) a method for improving the antithrombotic property of the material itself,
(2) A method of inducing an intima by inducing a living tissue after transplanting an artificial blood vessel to impart antithrombotic properties, and the like have been studied. However, in the method (1), although development of an antithrombotic polymer material such as a phase-separated structure or an antithrombotic agent-immobilized material is being studied, a material that exhibits good antithrombotic properties for a long period after transplantation. Has not been obtained.
In the method (2), in order to promote intimal formation after transplantation, a method for promoting invasion of living tissue or capillaries from outside the blood vessel is currently being studied.
【0006】人工血管の初期開存は、材料の抗血栓性が
いかなる初期相互作用を示すものであるかによって左右
される。人工血管を生体に移植すると、初期相互作用の
結果として内腔表面に血小板の付着等による初期血栓膜
が形成される。この初期血栓膜は、線維芽細胞による組
織治癒を受け、新生内皮細胞の増殖による新生内膜、あ
るいはコラーゲンやフィブリンが混在する偽内膜が形成
される。この内膜により長期抗血栓性が獲得され、長期
開存を得る。しかし、そのためには、人工血管の内腔表
面にできるだけ薄い初期血栓膜を安定して形成し、組織
治癒過程で形成される内膜を薄くすること、すなわち内
膜肥厚をきたさないようにすることが必要である。The initial patency of a vascular prosthesis depends on what initial interactions the material's antithrombotic properties exhibit. When an artificial blood vessel is transplanted into a living body, as a result of the initial interaction, an initial thrombus membrane is formed on the surface of the lumen due to adhesion of platelets and the like. This initial thrombus membrane undergoes tissue healing by fibroblasts, and a neointima due to proliferation of neoendothelial cells or a pseudointimal membrane in which collagen and fibrin are mixed is formed. This intima provides long-term antithrombotic properties and long-term patency. However, for that purpose, it is necessary to stably form the thinnest initial thrombus membrane on the luminal surface of the artificial blood vessel and thin the intimal membrane formed during the tissue healing process, that is, to prevent intimal thickening. is necessary.
【0007】ところで、従来使用されてきた延伸PTF
E製の人工血管は、先に述べたように、ある程度抗血栓
性に優れるものの、(1)の方法による抗血栓性の向上
には限度があり、しかも非付着性であるため、内膜形成
においても不利な点が生じてくる。前記した内膜は、例
えば、次のような順序で形成される。先ず、人工血管内
面に血小板の付着やフィブリンによる血栓膜が形成され
る。その後、移植後の血液反応が落ち着き、形成された
血栓膜は安定する。その上を、主として生体血管との吻
合部より、平滑筋細胞および内皮細胞が内膜として伸展
し、人工血管内面に内膜が形成される。By the way, conventionally used expanded PTF
As described above, the artificial blood vessel made of E has an excellent antithrombotic property to some extent, but the improvement of the antithrombotic property by the method (1) is limited, and is non-adhesive. There are also disadvantages in. The inner membrane described above is formed in the following order, for example. First, the adhesion of platelets and the thrombus membrane due to fibrin are formed on the inner surface of the artificial blood vessel. After that, the blood reaction after transplantation settles down, and the formed thrombus membrane becomes stable. Smooth muscle cells and endothelial cells extend as an intima mainly from the anastomosis part with the living blood vessel, and an intima is formed on the inner surface of the artificial blood vessel.
【0008】ところが、延伸PTFE製の人工血管にお
いては、最初に形成されるべき血栓膜がPTFEの非付
着性のために、人工血管内面に安定して形成されず、仮
に内膜が伸展してきても、人工血管と血栓膜との界面で
剥離を生じてしまう。その結果、剥離した血栓膜と内膜
によって再び血栓が誘起され、人工血管は、狭窄・閉塞
を起こしてしまう。一方、ポリエステル繊維編物や織物
からなる人工血管は、PTFEより付着性のよいポリエ
ステルを材料としているため、血栓膜の安定性には優れ
るものの、初期に形成される血栓膜が厚いため、内膜肥
厚をきたし、狭窄しやすいという問題を有している。However, in the expanded PTFE artificial blood vessel, the thrombus membrane to be formed first is not stably formed on the inner surface of the artificial blood vessel due to the non-adhesiveness of PTFE, and the intima may be extended. Also, peeling occurs at the interface between the artificial blood vessel and the thrombus membrane. As a result, thrombus is again induced by the separated thrombus membrane and intima, and the artificial blood vessel undergoes stenosis / occlusion. On the other hand, an artificial blood vessel made of polyester fiber knitted fabric or woven fabric is made of polyester, which has better adhesiveness than PTFE, so that the stability of the thrombus membrane is excellent, but the thickness of the thrombus membrane formed in the initial stage is thick, and therefore the intimal thickening However, there is a problem that the stenosis is likely to occur.
【0009】[0009]
【発明が解決しようとする課題】本発明の目的は、生体
血管と同様の内膜を、人工血管内面に薄く安定的に形成
し、特に内径6mm以下の小口径領域においても良好に
開存する人工血管を提供することにある。前記したとお
り、人工血管内面に薄く安定な内膜を形成するために
は、先ず、その前段階である血栓膜の形成過程で、薄く
安定な血栓膜を形成することが必要である。SUMMARY OF THE INVENTION An object of the present invention is to artificially form an intimal membrane similar to a living blood vessel on the inner surface of an artificial blood vessel thinly and stably, and particularly well in a small diameter region with an inner diameter of 6 mm or less. To provide blood vessels. As described above, in order to form a thin and stable intima on the inner surface of the artificial blood vessel, it is first necessary to form a thin and stable thrombus in the process of forming the thrombus, which is the preceding step.
【0010】本発明者は、前記従来技術の問題点を克服
するために鋭意研究した結果、繊維と該繊維によって互
いに連結された結節とからなる微細繊維状組織を有する
延伸PTFE多孔質チューブ製の人工血管の内腔表面
に、微細繊維状組織の切断・収縮および/または分解・
除去された部分により形成された凹凸構造を形成するこ
とにより、PTFEの抗血栓性を保持したまま、初期に
形成される血栓膜を安定に保持し得ることを見いだし
た。The present inventor has conducted extensive studies in order to overcome the above-mentioned problems of the prior art, and as a result, made of expanded PTFE porous tube having a fine fibrous structure composed of fibers and nodules connected to each other by the fibers. Cutting, contraction and / or decomposition of fine fibrous tissue on the inner surface of the artificial blood vessel
It was found that by forming an uneven structure formed by the removed portion, it is possible to stably hold the thrombus membrane initially formed while maintaining the antithrombotic property of PTFE.
【0011】特に、延伸PTFEチューブ製人工血管の
内腔表面の凹凸構造について、その凹部の平均深さを5
〜20μmの範囲とし、かつ、管状構造の長軸方向(血
流方向)の凹部の平均幅を10〜50μmの範囲とする
ことにより、薄い初期血栓膜を安定に形成し、保持でき
ることを見いだした。さらに、このような凹凸構造を形
成する方法として、内腔表面の微細繊維状組織の切断・
収縮および/または分解・除去を行う各種方法のあるこ
とを見いだした。本発明は、これらの知見に基づいて完
成するに至ったものである。Particularly, regarding the concavo-convex structure on the surface of the lumen of the expanded PTFE tube-made artificial blood vessel, the average depth of the concavities is 5
It was found that a thin initial thrombotic membrane can be stably formed and retained by setting the average initial width of the concave portion of the tubular structure in the long axis direction (blood flow direction) to be in the range of 10 to 50 μm. .. Furthermore, as a method of forming such a concavo-convex structure, cutting of fine fibrous tissue on the surface of the lumen is performed.
It has been found that there are various methods of shrinking and / or disassembling / removing. The present invention has been completed based on these findings.
【0012】[0012]
【課題を解決するための手段】かくして、本発明によれ
ば、繊維と該繊維によって互いに連結された結節とから
なる微細繊維状組織を有する管状四弗化エチレン樹脂多
孔質体製の人工血管において、少なくともその内腔表面
に微細繊維状組織の切断・収縮および/または分解・除
去された部分により形成された凹凸構造を有することを
特徴とする人工血管が提供される。Thus, according to the present invention, there is provided an artificial blood vessel made of a tubular tetrafluoroethylene resin porous body having a fine fibrous structure comprising fibers and nodules connected to each other by the fibers. An artificial blood vessel is provided, which has an uneven structure formed at least on the surface of its lumen by a cut / contracted and / or decomposed / removed portion of a fine fibrous tissue.
【0013】また、本発明によれば、繊維と該繊維によ
って互いに連結された結節とからなる微細繊維状組織を
有する管状四弗化エチレン樹脂多孔質体の少なくとも内
腔表面をアルカリ金属化合物の有機溶剤溶液で処理し、
微細繊維状組織を分解した後、分解物を除去して、少な
くとも内腔表面に凹凸構造を形成することを特徴とする
人工血管の製造方法が提供される。Further, according to the present invention, at least the inner surface of the tubular tetrafluoroethylene resin porous body having a fine fibrous structure composed of fibers and nodules connected to each other by the fibers is treated with an alkali metal compound organic compound. Treated with a solvent solution,
There is provided a method for producing an artificial blood vessel, which comprises decomposing a fine fibrous tissue and then removing the decomposed product to form an uneven structure at least on the surface of the lumen.
【0014】以下、本発明について詳述する。血栓形成
には多くの因子が関与するが、人工血管の場合、上記で
述べたようにPTFEやポリエステルといった材質と、
人工血管内面の形状、の2つが大きな要因となる。血液
は、内面が平滑な人工血管(生体血管も同様)では、流
れの方向が一方向に整った状態で流れるが、段差や径変
化など、人工血管の内面形状に変化があると流れが乱れ
て、局所的な渦流を起こす。この流れの乱れは、血栓形
成を誘発し、その度合は血管内面の形状変化の度合に依
存することになる。The present invention will be described in detail below. Many factors are involved in thrombus formation, but in the case of artificial blood vessels, materials such as PTFE and polyester, as described above,
The two major factors are the shape of the inner surface of the artificial blood vessel. Blood flows through an artificial blood vessel with a smooth inner surface (similar to a living blood vessel) with the flow direction aligned in one direction, but if there is a change in the inner surface shape of the artificial blood vessel, such as a step or diameter change, the flow is disturbed. And generate a local eddy current. This turbulence in the flow induces thrombus formation, the degree of which depends on the degree of shape change of the inner surface of the blood vessel.
【0015】従来、人工血管内面の形状変化による血栓
形成は、例えば、大口径のポリエステル製織物の人工血
管の場合、その内面を起毛させて治癒性を高めるという
形で利用されていたが、当然、平滑な内面に比して形成
される血栓膜の厚みが増すために、専らより大口径での
適用に限定され、小口径になるほど内面は平滑にする必
要があるとされてきた。つまり、このような人工血管
は、比較的厚い血栓膜や内膜を形成する目的で応用され
てきたといえる。Conventionally, thrombus formation by changing the shape of the inner surface of the artificial blood vessel has been used, for example, in the case of an artificial blood vessel of a polyester fabric having a large diameter, by raising the inner surface of the artificial blood vessel to enhance the healing property. Since the thickness of the thrombus film formed is increased as compared with a smooth inner surface, it has been exclusively limited to application with a larger diameter, and it has been said that the smaller the diameter, the smoother the inner surface needs to be. That is, it can be said that such an artificial blood vessel has been applied for the purpose of forming a relatively thick thrombus membrane or intima.
【0016】本発明者らは、むしろ、PTFEの非付着
性、低血栓性という化学的性質に、内面形状変化による
血栓膜の安定性という物理的性質を与えることで、血栓
膜や内膜が剥れて安定に付着しないという延伸PTFE
製人工血管の欠点を克服できないかと考えるに至った。
そして、本発明者らは、鋭意研究の結果、延伸PTFE
製人工血管の内腔表面に凹凸構造を付与し、この凹凸の
度合を変化させることにより、人工血管の内面に形成さ
れる血栓膜の厚みを制御できることを見いだした。The present inventors rather give the physical property of stability of the thrombotic membrane due to the change in shape of the inner surface to the chemical property of PTFE which is non-adhesive and low thrombotic, so that Stretched PTFE that does not peel off and adhere stably
We came to think that we could overcome the drawbacks of artificial blood vessels.
As a result of earnest research, the present inventors have found that expanded PTFE
It was found that the thickness of the thrombus membrane formed on the inner surface of the artificial blood vessel can be controlled by imparting an uneven structure to the inner surface of the artificial blood vessel, and changing the degree of the unevenness.
【0017】さらに、本発明者らは、鋭意研究の結果、
この内面に付与した凹凸構造は、初期血栓膜を人工血管
内面に安定に保持すること、この血栓膜の安定性は、そ
の後の人工血管の治癒過程でこの血栓膜と置換していく
内膜の治癒速度を促進すること、また、凹凸構造は、治
癒した人工血管内面の内膜を安定に保持する効果がある
こと、を見出した。Further, as a result of earnest research, the present inventors have found that
The concavo-convex structure provided on this inner surface stably holds the initial thrombus membrane on the inner surface of the artificial blood vessel, and the stability of this thrombus membrane is determined by the inner membrane that replaces this thrombus membrane during the subsequent healing process of the artificial blood vessel. It was found that the healing rate is promoted and that the uneven structure has an effect of stably retaining the intima of the healed inner surface of the artificial blood vessel.
【0018】このような凹凸構造の形成による効果は、
凹凸構造化による接着面積拡大による一種のアンカリン
グ効果ということができ、これによって、PTFEの材
質的な特徴である非付着性を改善し、血栓膜と内膜の剥
がれ等を防ぐという目的を実現することが可能となる。The effect of forming such an uneven structure is as follows.
It can be said that it is a kind of anchoring effect by expanding the adhesion area due to the uneven structure, thereby improving the non-adhesiveness that is a characteristic feature of PTFE and realizing the purpose of preventing peeling of the thrombus membrane and intima. It becomes possible to do.
【0019】本発明の延伸PTFE製人工血管は、図1
にその模式図を示すように、内腔表面に多数の凹部
(3)と凸部(4)が形成されている。このような凹凸
構造は、図2に示すように、繊維(1)と該繊維によっ
て互いに連結された結節(2)とからなる微細繊維状組
織を有する管状四弗化エチレン樹脂多孔質体製の内腔表
面を処理して、微細繊維状組織を切断または分解除去し
た凹部(3)と、結節部分が残存・収縮した凸部(4)
を形成することにより付与することができる。The expanded PTFE artificial blood vessel of the present invention is shown in FIG.
As shown in the schematic diagram, a large number of concave portions (3) and convex portions (4) are formed on the surface of the lumen. As shown in FIG. 2, such a concavo-convex structure is made of a tubular tetrafluoroethylene resin porous body having a fine fibrous structure composed of fibers (1) and nodules (2) connected to each other by the fibers. Recesses (3) in which the surface of the lumen is treated to cut or decompose and remove fine fibrous tissue, and protrusions (4) in which nodules remain or contract
Can be imparted by forming.
【0020】本発明の人工血管に付与される内腔表面の
凹凸構造は、血流方向(管状構造の長軸方向)の凹部の
平均幅が好ましくは10〜100μm、より好ましくは
10〜50μmである。血流方向の凹部の平均幅が小さ
過ぎると、血栓膜の形成と、その安定化の改善効果が小
さく、逆に、100μmを越えるような大きな幅になる
と、血流の乱れが大きく、厚い血栓膜が急速に成長して
しまう。In the concavo-convex structure on the surface of the lumen given to the artificial blood vessel of the present invention, the average width of the concave portions in the blood flow direction (long axis direction of the tubular structure) is preferably 10 to 100 µm, more preferably 10 to 50 µm. is there. If the average width of the concave portions in the blood flow direction is too small, the effect of improving the formation and stabilization of the thrombus membrane is small, and conversely, if the width is larger than 100 μm, the blood flow is greatly disturbed and a thick thrombus is formed. The film grows rapidly.
【0021】また、凹凸構造の凹部の平均深さは、好ま
しくは3〜30μm、より好ましくは5〜20μmであ
る。凹部の平均深さが小さ過ぎると、血栓膜の形成と、
その安定化の改善効果が小さく、逆に、大き過ぎると、
初期血栓膜が厚くなり過ぎて早期閉塞を起こす頻度が高
くなる。例えば、血流方向の凹部の平均幅が20μm超
過の場合には、凹部の平均深さ30μm以上で形成血栓
膜が厚くなり過ぎて早期閉塞を起こす頻度が若干高くな
る。ただし、血流方向の凹部の平均幅20μm以下の場
合は、凹部の平均深さが30μm以上でも問題はない。
しかし、30μmを越えて深くしても、血栓膜に対する
安定化効果には差がないことと、短い幅で深い凹凸構造
を形成することは製造上難しいことから、通常、平均深
さを3〜30μmとし、好ましくは5〜20μmとす
る。The average depth of the concave portions of the concavo-convex structure is preferably 3 to 30 μm, more preferably 5 to 20 μm. If the average depth of the recesses is too small, formation of a thrombus film and
If the stabilization effect is small, on the contrary, if it is too large,
The initial thrombotic membrane becomes too thick and premature obstruction occurs more frequently. For example, when the average width of the recesses in the blood flow direction exceeds 20 μm, the formed thrombus membrane becomes too thick at an average depth of the recesses of 30 μm or more, and the frequency of early occlusion slightly increases. However, when the average width of the recesses in the blood flow direction is 20 μm or less, there is no problem even if the average depth of the recesses is 30 μm or more.
However, even if the depth exceeds 30 μm, there is no difference in the stabilizing effect on the thrombus membrane, and it is difficult to form a deep uneven structure with a short width in terms of manufacturing. The thickness is 30 μm, preferably 5 to 20 μm.
【0022】以上のことから、内腔表面に形成された凹
凸構造は、平均深さ5〜20μm、かつ、管状構造の長
軸方向の平均幅10〜50μmの凹部を有するように制
御することが望ましい。From the above, the concavo-convex structure formed on the inner surface of the lumen can be controlled so as to have recesses having an average depth of 5 to 20 μm and an average width of 10 to 50 μm in the longitudinal direction of the tubular structure. desirable.
【0023】本発明の人工血管は、例えば、特公昭42
−13560号に記載の方法により延伸PTFEチュー
ブ(PTFE多孔質チューブ)を作製し、次いで、内腔
表面となる表面部分に凹凸構造を形成する処理を行うこ
とにより製造することができる。The artificial blood vessel of the present invention is, for example, Japanese Patent Publication No.
It can be manufactured by producing an expanded PTFE tube (PTFE porous tube) by the method described in No. -13560, and then performing a treatment of forming a concavo-convex structure on the surface portion to be the lumen surface.
【0024】先ず、PTFE未燒結粉末に液状潤滑剤を
混和し、押出・圧延等によりチューブ状に予備成形す
る。この成形体から液状潤滑剤を除去し、または除去す
ることなく、少なくとも一軸方向に延伸する。次に、成
形体を収縮しないように固定した状態で、樹脂の融点で
ある327℃以上に加熱して、延伸した構造を燒結固定
すると、強度の向上したPTFE多孔質チューブが得ら
れる。このPTFE多孔質チューブは、繊維と該繊維に
よって互いに連結された結節とからなる微細繊維状組織
を有する多孔質のものである。First, a liquid lubricant is mixed with PTFE unsintered powder, and preformed into a tubular shape by extrusion, rolling or the like. The liquid lubricant is removed from the molded body or is stretched in at least uniaxial direction without being removed. Next, in a state where the molded body is fixed so as not to shrink, it is heated to 327 ° C. or higher, which is the melting point of the resin, and the stretched structure is sintered and fixed to obtain a PTFE porous tube having improved strength. This PTFE porous tube is a porous tube having a fine fibrous structure composed of fibers and nodules connected to each other by the fibers.
【0025】本発明品は、この延伸PTFE製人工血管
の内面に凹凸構造を付与することで得られるが、PTF
Eの性状を変えずに凹凸構造を付与するために、上記微
細繊維構造の切断・収縮および/または分解・除去され
た部分を設ける。このような凹凸構造の形成方法として
は、例えば、(1)特公昭58−1656号に記載の方
法、すなわち、加熱燒結工程でPTFE多孔質体の一部
分を他の部分より高い温度に加熱するか、あるいは全体
を均一に加熱燒結した後、さらにPTFE多孔質体の一
部分を加熱して、微細繊維の切断や融着合体、および結
節間の収縮による結節の融着合体を起こさせる方法、
(2)特公昭63−23215号に記載の方法、すなわ
ち、PTFE多孔質体の表面を熱風、火炎、炭酸ガスレ
ーザー等によりPTFEの熱分解温度以上に加熱して表
面の一部分を分解除去する方法、を利用することができ
る。The product of the present invention can be obtained by imparting an uneven structure to the inner surface of the expanded PTFE artificial blood vessel.
In order to impart an uneven structure without changing the properties of E, the cut / shrinked and / or decomposed / removed portion of the fine fiber structure is provided. Examples of the method for forming such a concavo-convex structure include (1) the method described in JP-B-58-1656, that is, whether a part of the PTFE porous body is heated to a higher temperature than the other part in the heating and sintering step. Or, after uniformly heating and sintering the whole, a part of the PTFE porous body is further heated to cause cutting or fusion bonding of fine fibers, and fusion bonding of knots due to shrinkage between the knots,
(2) The method described in JP-B-63-23215, that is, the method in which the surface of the PTFE porous body is heated to a temperature higher than the thermal decomposition temperature of PTFE by hot air, flame, carbon dioxide laser or the like to decompose and remove a part of the surface. , Can be used.
【0026】これらの方法によりPTFE多孔質体の一
部分を加熱すると、熱によってPTFE繊維の切断が起
こって広がった結節間が凹部となり、他の結節間は収縮
し、結節が寄り集まって凸部となるが、繊維の切断時に
PTFEの分解が起こり、ガス化して除去される。70
0〜1000℃の加熱炉で熱処理する場合には、繊維の
分解除去はあまり起こらず、特に低温で行うと殆ど起こ
らない。これに対して、直接ガスバーナーの火炎で処理
する場合には、切断・収縮よりも繊維の分解除去が優位
となる。通常は、微細繊維状組織の切断・収縮と分解除
去の両方が生じる。When a part of the PTFE porous body is heated by these methods, the PTFE fibers are cut by heat to spread the internodal spaces into recesses, the other internodal spaces shrink, and the nodules gather to form convex parts. However, PTFE is decomposed when the fiber is cut, and is gasified and removed. 70
When heat treatment is performed in a heating furnace at 0 to 1000 ° C., decomposition and removal of fibers do not occur so much, and particularly when performed at a low temperature, they hardly occur. On the other hand, when directly treating with the flame of the gas burner, the decomposition and removal of the fiber is superior to the cutting and shrinking. Normally, both cutting and shrinking of fine fibrous tissue and decomposition and removal occur.
【0027】これらの熱処理による表面加工において、
より高温で素早く加熱すると細かい凹凸構造になり、よ
り低温でゆっくり加熱すると粗い凹凸構造となる。つま
り処理温度と速度を制御することで、所望の形状の凹凸
構造を付与することが可能である。In the surface processing by these heat treatments,
Rapid heating at a higher temperature produces a fine relief structure, and slower heating at a lower temperature produces a rough relief structure. In other words, by controlling the processing temperature and speed, it is possible to provide a concavo-convex structure having a desired shape.
【0028】ただし、これらの方法は、熱などのエネル
ギーをPTFE多孔質体の一部に与える必要があるた
め、これを細いPTFE多孔質チューブの内腔表面に与
えることは困難であり、特別の工夫を要する。PTFE
多孔質チューブの内腔表面に凹凸構造を付与する方法と
しては、例えば、PTFE多孔質チューブの外表面に熱
処理を行って凹凸構造を付与してから内外面を反転させ
る方法がある。この方法では、内周と外周の長さの違い
から歪みが生じて、チューブがつぶれることがあるが、
この場合、ステンレス棒等を内腔に挿入して、微細繊維
状組織構造に影響がでない程度に加熱してやるとよい。However, in these methods, it is difficult to apply the energy such as heat to a part of the PTFE porous body, so that it is difficult to apply the energy to the inner surface of the thin PTFE porous tube. Requires devising. PTFE
As a method for imparting an uneven structure to the inner surface of the porous tube, for example, there is a method in which the outer surface of the PTFE porous tube is heat-treated to provide the uneven structure and then the inner and outer surfaces are inverted. In this method, distortion may occur due to the difference in length between the inner circumference and the outer circumference, and the tube may collapse,
In this case, it is advisable to insert a stainless rod or the like into the lumen and heat it to such an extent that the fine fibrous tissue structure is not affected.
【0029】また、これら熱による微細繊維状組織の切
断・収縮と分解・除去以外に、化学的処理によってPT
FE繊維を分解・除去する方法がある。具体的には、メ
チルリチウム、あるいはナトリウムやカリウムなどのア
ルカリ金属とナフタレンやアントラセンなどのアニオン
ラジカルとの錯体などのアルカリ金属化合物は、PTF
Eを分解することができる。本発明者らは、アルカリ金
属化合物の種類、有機溶剤溶液の濃度、処理時間、温度
などを適正に制御することで、PTFE多孔質チューブ
の微細繊維状組織の結節を破壊せずに、繊維のみを切断
することができることを見いだした。Further, in addition to the cutting / shrinking and the decomposition / removal of the fine fibrous tissue by the heat, the PT is produced by a chemical treatment.
There is a method to decompose and remove the FE fiber. Specifically, an alkali metal compound such as methyllithium or a complex of an alkali metal such as sodium or potassium with an anion radical such as naphthalene or anthracene is a PTF.
E can be decomposed. The inventors of the present invention properly control the type of alkali metal compound, the concentration of the organic solvent solution, the treatment time, the temperature, etc., without destroying the nodules of the fine fibrous structure of the PTFE porous tube, and only the fibers Found that you can disconnect.
【0030】化学処理の具体的条件としては、例えば、
メチルリチウム、ナトリウム−ナフタレン錯体、ナトリ
ウム−アントラセン錯体などのアルカリ金属化合物のテ
トラヒドロフランなどの有機溶剤溶液(濃度0.1〜1
0モル/リットル)に、PTFE多孔質チューブを浸漬
し、液温20〜68℃で、5〜60分間程度保持する。Specific conditions of the chemical treatment include, for example,
A solution of an alkali metal compound such as methyllithium, sodium-naphthalene complex or sodium-anthracene complex in an organic solvent such as tetrahydrofuran (concentration of 0.1 to 1).
The PTFE porous tube is immersed in 0 mol / liter) and kept at a liquid temperature of 20 to 68 ° C. for about 5 to 60 minutes.
【0031】また、これらの化学処理でPTFE多孔質
チューブ表面に生成するフッ化ナトリウム、炭素−炭素
二重結合等のPTFEの分解物、これらとナフタレン、
アントラセンとの重合物などの分解産物は、過酸化水素
や次亜塩素酸ソーダによる酸化分解によって除去可能で
ある。Further, sodium fluoride generated on the surface of the PTFE porous tube by these chemical treatments, a decomposition product of PTFE such as a carbon-carbon double bond, these and naphthalene,
Decomposition products such as a polymer with anthracene can be removed by oxidative decomposition with hydrogen peroxide or sodium hypochlorite.
【0032】この化学処理方法は、熱を利用する方法に
比して、内外面反転やそれに伴う管状構造の歪みの補正
などの手間が不要で、特に本発明の目的とする内径3m
m以下といった細い径の人工血管には、有用な方法であ
る。This chemical treatment method does not require labor such as inversion of the inner and outer surfaces and correction of the distortion of the tubular structure due to it, as compared with the method of utilizing heat, and particularly the inner diameter of 3 m which is the object of the present invention.
This is a useful method for artificial blood vessels having a small diameter of m or less.
【0033】なお、本発明の人工血管は、少なくともそ
の内腔表面に凹凸構造が形成されていることが必要であ
り、内外両面に凹凸構造が形成されていてもよい。内外
両面に凹凸構造が形成されていても、通常の人工血管の
膜厚(300〜1000mm程度)では、大きな強度低
下は生じない。また、外表面にも凹凸構造を形成すれ
ば、人工血管の外表面からも器質化、治癒(繊維芽細胞
等組織の侵入性)が進行する。The artificial blood vessel of the present invention is required to have a concavo-convex structure on at least the surface of its inner cavity, and the concavo-convex structure may be formed on both inner and outer surfaces. Even if the concavo-convex structure is formed on both the inner and outer surfaces, a large decrease in strength does not occur with the thickness of an ordinary artificial blood vessel (about 300 to 1000 mm). In addition, if a concavo-convex structure is formed also on the outer surface, organizing and healing (invasion of tissues such as fibroblasts) will proceed from the outer surface of the artificial blood vessel.
【0034】前記化学処理により人工血管の内腔表面の
みを処理するには、例えば、PTFE多孔質チューブの
一端を封止して、他端からポンプや注射器で処理液を注
入すればよい。処理液にPTFE多孔質チューブを浸漬
すれば、内外両面に凹凸構造が形成される。To treat only the inner surface of the artificial blood vessel by the chemical treatment, for example, one end of the PTFE porous tube may be sealed and the treatment liquid may be injected from the other end by a pump or a syringe. By immersing the PTFE porous tube in the treatment liquid, an uneven structure is formed on both inner and outer surfaces.
【0035】以上のような、熱や化学処理によるPTF
E内腔表面への凹凸構造の付与は、いずれもPTFE多
孔質チューブ内腔表面の微細繊維状組織自身を加工する
方法である。つまり、PTFE多孔質チューブ内腔表面
の多孔質構造において、結節部分を凸部に、繊維部分を
凹部に加工する方法である。したがって、付与できる凹
凸構造は、凹凸構造を付与する前のPTFE多孔質チュ
ーブ内腔表面の結節間の距離などの組織構造によって制
限される。例えば、結節間距離が30μmより長いPT
FE多孔質チューブでは、幅30μm以下の凹部を形成
することは、事実上不可能である。このため、所望の凹
部平均深さや平均幅を有する凹凸構造を形成するために
は、内腔表面の微細繊維状組織、特に結節間距離を変え
たPTFE多孔質チューブを用意する必要があるが、例
えば、特公昭42−13560号に記載の方法によれ
ば、延伸工程においてその延伸倍率を変えることなどに
よって、多様な多孔質構造のPTFE多孔質チューブを
調製することができる。PTF by heat or chemical treatment as described above
The provision of the concavo-convex structure on the inner surface of the E lumen is a method of processing the fine fibrous tissue itself on the inner surface of the PTFE porous tube. In other words, in the porous structure of the inner surface of the PTFE porous tube, the knotted portion is formed into a convex portion and the fiber portion is formed into a concave portion. Therefore, the concavo-convex structure that can be applied is limited by the tissue structure such as the distance between the nodules on the surface of the PTFE porous tube before the concavo-convex structure is applied. For example, PT with internodal distance longer than 30 μm
With a FE porous tube, it is virtually impossible to form a recess having a width of 30 μm or less. Therefore, in order to form a concavo-convex structure having a desired average depth and width of the recesses, it is necessary to prepare a fine fibrous tissue on the surface of the lumen, particularly a PTFE porous tube with a different internodal distance, For example, according to the method described in Japanese Examined Patent Publication No. 42-13560, it is possible to prepare PTFE porous tubes having various porous structures by changing the stretching ratio in the stretching step.
【0036】以上のような製法で得た本発明品には、次
のような特徴がある。 (1)PTFE多孔質チューブに、PTFE以外の物質
を付与または付加するのではなく、チューブの内表面自
身を加工する方法により得られるものであるため、PT
FE自身の持つ人工血管としての特性を阻害しない。 (2)多孔質チューブの内腔表面に凹凸構造が一体的に
設けられているため、凹凸構造部分の剥離・分離等の問
題がない。The product of the present invention obtained by the above manufacturing method has the following features. (1) PT Since it is obtained by a method of processing the inner surface of the tube itself, rather than adding or adding a substance other than PTFE to the porous tube, PT
It does not hinder the characteristics of FE itself as an artificial blood vessel. (2) Since the concavo-convex structure is integrally provided on the inner surface of the porous tube, there is no problem such as peeling or separation of the concavo-convex structure portion.
【0037】これらの特徴により、本発明品は、延伸P
TFE製人工血管の長所である、非付着性に基づく薄い
血栓膜を形成する性質を保持したまま、その内面凹凸構
造によって形成血栓膜を安定に保持することが可能であ
り、その目的である、人工血管内腔の安定な内膜形成を
実現することができる。Due to these characteristics, the product of the present invention has a stretched P
The advantage of the TFE artificial blood vessel, while maintaining the property of forming a thin thrombus film based on non-adhesiveness, it is possible to stably hold the formed thrombus film by its inner surface concavo-convex structure. Stable intimal formation of the artificial blood vessel lumen can be realized.
【0038】[0038]
【実施例】以下、本発明について、実施例および比較例
を挙げて具体的に説明するが、本発明は、これらの実施
例のみに限定されるものではない。EXAMPLES The present invention will be specifically described below with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
【0039】なお、物性の測定方法は、以下の通りであ
る。 〈平均繊維長〉走査型電子顕微鏡で、結節間距離を測定
し、その平均値を算出した。The methods for measuring the physical properties are as follows. <Average fiber length> The internodal distance was measured with a scanning electron microscope, and the average value was calculated.
【0040】〈バブルポイント〉人工血管をイソプロピ
ルアルコールに浸漬して、管壁の孔内をイソプロピルア
ルコールで充満した後、チューブの内側より徐々に空気
圧を負荷したときに、初めて気泡が出てくる時の圧力を
測定した。<Bubble point> When the artificial blood vessel is dipped in isopropyl alcohol and the hole in the tube wall is filled with isopropyl alcohol, and air pressure is gradually applied from the inside of the tube, the first time air bubbles come out. Was measured.
【0041】〈漏水圧〉人工血管の内側から徐々に水圧
を負荷したときに、初めて水が人工血管外壁から出てく
る時の水圧を測定した。<Water Leakage Pressure> When water pressure was gradually applied from the inside of the artificial blood vessel, the water pressure when water came out from the outer wall of the artificial blood vessel for the first time was measured.
【0042】〈開存率〉人工血管を移植し、ある一定期
間生かした後の、その時点で血流が認められた人工血管
の本数の、移植した人工血管全数に対する比率で示し
た。<Patency> The artificial blood vessel was transplanted and kept alive for a certain period of time, and the ratio of the number of artificial blood vessels in which blood flow was observed at that time to the total number of transplanted artificial blood vessels was shown.
【0043】〈血栓厚み〉人工血管を移植し、ある一定
期間生かした後に取りだした人工血管をホルマリン固定
後、臨界点乾燥を施し、走査型電子顕微鏡で、長軸方向
に切断した断面の内面に付着した血栓膜の厚みを測定
し、その平均値をもって表示した。<Thrombus Thickness> An artificial blood vessel was transplanted, and after being kept alive for a certain period of time, the artificial blood vessel was fixed with formalin, dried at a critical point, and then, on a scanning electron microscope, the inner surface of the cross section cut in the longitudinal direction was examined. The thickness of the attached thrombus membrane was measured, and the average value was displayed.
【0044】〈内皮細胞被覆率〉同上サンプルの内表面
を血管内皮細胞が被覆している面積の、内表面全面積に
対する比率で示した。<Endothelial Cell Coverage> Same as above The ratio of the area of the inner surface of the sample coated with vascular endothelial cells to the total area of the inner surface is shown.
【0045】[実施例1]PTFEファインパウダー
(ダイキン工業社製、PTFEファインパウダーF10
4)100重量部に対して、ドライゾール20重量部を
助剤として混合し、ラム押出機によってチューブ状に成
形した後に、ドライゾールを50℃で、48時間乾燥さ
せた。この押出チューブを電気炉中、炉温350℃、炉
内滞在時間120秒の条件で加熱しながら250%延伸
し、気孔率65%、平均繊維長10μm、内径2mm
φ、外径3mmφのPTFE多孔質チューブを得た。[Example 1] PTFE fine powder (manufactured by Daikin Industries, Ltd., PTFE fine powder F10)
4) 20 parts by weight of dryzole was mixed with 100 parts by weight as an auxiliary agent and molded into a tube by a ram extruder, and then dryzol was dried at 50 ° C. for 48 hours. This extruded tube was stretched 250% while being heated in an electric furnace under conditions of a furnace temperature of 350 ° C. and a residence time in the furnace of 120 seconds, a porosity of 65%, an average fiber length of 10 μm, and an inner diameter of 2 mm.
A PTFE porous tube with φ and an outer diameter of 3 mmφ was obtained.
【0046】次いで、プロパンガス流量15〜18リッ
トル/分、供給空気流量12リットル/分で、六口バー
ナー(バーナー口がチューブが通過する中心点を向くよ
うに6ケのバーナーを同一円周上に均等に配置したも
の)の中心に火炎を集中させ、ここに上記PTFE多孔
質チューブを線速15m/分で通過させ、外表面に凹凸
構造を付与した。その後にチューブの内外面を反転さ
せ、チューブ内に外径2mmφのステンレス棒を挿入
し、電気炉中、炉温800℃、炉内滞在時間15秒の条
件で加熱することで、内外面の歪みを解消し、管状に復
元した。この結果、内径2mmφ、外径3mmφ、内腔
表面に凹部の管状構造の長軸方向の平均幅10μm、平
均深さ5μmの凹凸構造を有するPTFE多孔質チュー
ブ製の人工血管を得た。Next, with a propane gas flow rate of 15 to 18 liters / minute and a supply air flow rate of 12 liters / minute, a six-port burner (six burners on the same circumference so that the burner port faces the central point through which the tube passes). The flame was concentrated in the center of (the ones evenly arranged in) and passed through the PTFE porous tube at a linear velocity of 15 m / min to give an uneven structure to the outer surface. After that, the inner and outer surfaces of the tube are turned over, a stainless rod with an outer diameter of 2 mmφ is inserted into the tube, and the inner and outer surfaces are distorted by heating in an electric furnace at a furnace temperature of 800 ° C. and a residence time in the furnace of 15 seconds. Was canceled and it was restored to a tubular shape. As a result, an artificial blood vessel made of a PTFE porous tube having an inner diameter of 2 mmφ, an outer diameter of 3 mmφ, a concave-convex tubular structure having an average width of 10 μm in the long axis direction and an average depth of 5 μm on the inner surface of the lumen was obtained.
【0047】[実施例2]実施例1と同様の凹凸構造付
与前のPTFE多孔質チューブを用い、液温60℃のナ
トリウム−ナフタレン錯体のテトラヒドロフラン溶液に
30分間浸漬した後に、十分に水洗浄後、60℃の30
%過酸化水素水に24時間浸漬し、内径2mmφ、外径
3mmφ、内腔表面に凹部の平均幅10μm、平均深さ
20μmの凹凸構造を有するPTFE多孔質チューブ製
の人工血管を得た。[Example 2] Using the same PTFE porous tube as in Example 1 which had not been provided with the concavo-convex structure, it was immersed in a tetrahydrofuran solution of a sodium-naphthalene complex at a liquid temperature of 60 ° C for 30 minutes, and then thoroughly washed with water. , 60 ℃ 30
% Aqueous solution of hydrogen peroxide for 24 hours to obtain an artificial blood vessel made of a PTFE porous tube having an inner diameter of 2 mmφ, an outer diameter of 3 mmφ and a concave-convex structure with an average width of recesses of 10 μm and an average depth of 20 μm on the inner surface of the lumen.
【0048】[実施例3]PTFEファインパウダー
(ダイキン工業社製、PTFEファインパウダーF10
4)100重量部に対して、ドライゾール23重量部を
助剤として混合し、ラム押出機によってチューブ状に成
形した後に、ドライゾールを50℃、48時間で乾燥さ
せた。この押出チューブを電気炉中、炉温350℃、炉
内滞在時間120秒の条件で加熱しながら500%延伸
し、気孔率75%、平均繊維長30μm、内径2mm
φ、外径3mmφのPTFE多孔質チューブを得た。[Example 3] PTFE fine powder (manufactured by Daikin Industries, Ltd., PTFE fine powder F10)
4) With respect to 100 parts by weight, 23 parts by weight of DRYSOL was mixed as an auxiliary agent, and the mixture was molded into a tube by a ram extruder, and then DRYSOL was dried at 50 ° C. for 48 hours. This extruded tube was stretched by 500% while being heated in an electric furnace under the conditions of a furnace temperature of 350 ° C. and a residence time in the furnace of 120 seconds, a porosity of 75%, an average fiber length of 30 μm, and an inner diameter of 2 mm.
A PTFE porous tube with φ and an outer diameter of 3 mmφ was obtained.
【0049】次いで、線速を12m/分としたこと以外
は、実施例1と同様のプロパンガスバーナーによる凹凸
構造付与処理を行い、実施例1と同様に、内外面反転、
加熱による内外面の歪みの除去を行い、内径2mmφ、
外径3mmφ、内腔表面に凹部の管状構造の長軸方向の
平均幅30μm、平均深さ20μmの凹凸構造を有する
PTFE多孔質チューブ製の人工血管を得た。Then, the same process as in Example 1 was performed by using the propane gas burner except that the linear velocity was set to 12 m / min.
Distortion of the inner and outer surfaces due to heating is removed, and the inner diameter is 2 mmφ,
An artificial blood vessel made of a PTFE porous tube having an outer diameter of 3 mmφ, a concave-convex structure having a concave-convex structure on the surface of the inner cavity with an average width of 30 μm in the long axis direction and an average depth of 20 μm was obtained.
【0050】[実施例4]PTFEファインパウダー
(ダイキン工業社製、PTFEファインパウダーF10
4)100重量部に対して、ドライゾール23重量部を
助剤として混合し、ラム押出機によってチューブ状に成
形した後に、ドライゾールを50℃、48時間で乾燥さ
せた。この押出チューブを電気炉中、炉温350℃、炉
内滞在時間120秒の条件で加熱しながら700%延伸
し、気孔率77%、平均繊維長50μm、内径2mm
φ、外径3mmφのPTFE多孔質チューブを得た。[Example 4] PTFE fine powder (manufactured by Daikin Industries, Ltd., PTFE fine powder F10)
4) With respect to 100 parts by weight, 23 parts by weight of DRYSOL was mixed as an auxiliary agent, and the mixture was molded into a tube by a ram extruder, and then DRYSOL was dried at 50 ° C. for 48 hours. This extruded tube was stretched 700% while being heated in an electric furnace under the conditions of a furnace temperature of 350 ° C. and a residence time in the furnace of 120 seconds, a porosity of 77%, an average fiber length of 50 μm, and an inner diameter of 2 mm.
A PTFE porous tube with φ and an outer diameter of 3 mmφ was obtained.
【0051】次いで、ナトリウム−ナフタレン錯体溶液
への浸漬時間を20分間としてこと以外は、実施例2と
同様にして、内径2mmφ、外径3mmφ、内腔表面に
凹部の管状構造の長軸方向の平均幅50μm、平均深さ
20μmの凹凸構造を有するPTFE多孔質チューブ製
の人工血管を得た。Then, in the same manner as in Example 2 except that the immersion time in the sodium-naphthalene complex solution was set to 20 minutes, the inner diameter was 2 mmφ, the outer diameter was 3 mmφ, and the inner surface of the tubular structure having a recessed portion in the longitudinal direction was formed. An artificial blood vessel made of a PTFE porous tube having an uneven structure with an average width of 50 μm and an average depth of 20 μm was obtained.
【0052】[比較例1]実施例1で用いた、凹凸構造
付与前の、気孔率65%、平均繊維長10μm、内径2
mmφ、外径3mmφのPTFE多孔質チューブを比較
例1とした。[Comparative Example 1] The porosity of 65%, the average fiber length of 10 μm, and the inner diameter of 2 used in Example 1 before the concavo-convex structure was provided.
Comparative Example 1 was a PTFE porous tube having a mmφ and an outer diameter of 3 mmφ.
【0053】[比較例2]実施例3で用いた、凹凸構造
付与前の、気孔率75%、平均繊維長30μm、内径2
mmφ、外径3mmφのPTFE多孔質チューブを比較
例2とした。[Comparative Example 2] The porosity of 75%, the average fiber length of 30 μm and the inner diameter of 2 used in Example 3 before the concavo-convex structure was provided.
Comparative Example 2 was a PTFE porous tube having a diameter of 3 mm and an outer diameter of 3 mm.
【0054】[比較例3]実施例4で用いた、凹凸構造
付与前の、気孔率77%、平均繊維長50μm、内径2
mmφ、外径3mmφのPTFE多孔質チューブを比較
例3とした。[Comparative Example 3] The porosity of 77%, the average fiber length of 50 μm, and the inner diameter of 2 used in Example 4 before the concavo-convex structure was provided.
Comparative Example 3 was a PTFE porous tube having a mmφ and an outer diameter of 3 mmφ.
【0055】[比較例4]実施例3で用いたPTFE多
孔質チューブを用い、線速を10m/分としたこと以外
は、実施例1と同様のプロパンガスバーナーによる凹凸
構造付与処理を行い、実施例1と同様に、内外面反転、
加熱による内外面の歪みの除去を行って、内径2mm
φ、外径3mmφ、内腔表面に凹部の管状構造の長軸方
向の平均幅30μm、平均深さ30μmの凹凸構造を有
するPTFE多孔質チューブ製の人工血管を得た。これ
を比較例4とした。[Comparative Example 4] Using the PTFE porous tube used in Example 3, the concavo-convex structure was imparted by the same propane gas burner as in Example 1 except that the linear velocity was set to 10 m / min. Similar to the first embodiment, the inner and outer surfaces are reversed,
Internal diameter is 2 mm after removing the distortion of the inner and outer surfaces by heating.
An artificial blood vessel made of a PTFE porous tube having a concavo-convex structure of φ, an outer diameter of 3 mmφ, and an inner cavity surface having a concave-convex tubular structure with an average width of 30 μm in the long axis direction and an average depth of 30 μm was obtained. This was designated as Comparative Example 4.
【0056】[比較例5]実施例3で用いたPTFE多
孔質チューブを用い、プロパンガス流量12〜15リッ
トル/分で線速を7m/分としたこと以外は、実施例1
と同様のプロパンガスバーナーによる凹凸構造付与処理
を行ない、実施例1と同様に、内外面反転、加熱による
内外面の歪みの除去を行って、内径2mmφ、外径3m
mφ、内腔表面に凹部の管状構造の長軸方向の平均幅9
0μm、平均深さ30μmの凹凸構造を有するPTFE
多孔質チューブ製の人工血管を得た。これを比較例5と
した。Comparative Example 5 Example 1 was repeated except that the PTFE porous tube used in Example 3 was used and the linear velocity was 7 m / min at a propane gas flow rate of 12 to 15 liters / min.
The same propane gas burner is used to apply the concavo-convex structure, the inner and outer surfaces are reversed and the inner and outer surface strains are removed by heating in the same manner as in Example 1, and the inner diameter is 2 mmφ and the outer diameter is 3 m.
mφ, the average width in the major axis direction of the tubular structure of the concave portion on the surface of the lumen 9
PTFE having an uneven structure of 0 μm and average depth of 30 μm
An artificial blood vessel made of a porous tube was obtained. This was designated as Comparative Example 5.
【0057】(移植実験)前記各実施例および比較例で
得た人工血管を、それぞれ体重13〜15kgのウサギ
の頸動脈に、移植長2cmで移植を行った。移植後5
分、1時間、24時間、6週間成育後、該人工血管を取
り出し、開存率を調査した後、ホルマリン固定後、臨界
点乾燥を行い、走査型電子顕微鏡で、人工血管内面の形
成血栓膜の厚みを観察・測定した。また、移植6週後の
サンプルでは、内皮細胞被覆率を観察・測定した。同様
に、病理組織標本を作製し、器質化の状態を観察した。(Transplantation Experiment) The artificial blood vessels obtained in the above Examples and Comparative Examples were transplanted into a carotid artery of a rabbit having a body weight of 13 to 15 kg at a transplantation length of 2 cm. 5 after transplant
After 1 minute, 24 hours, 6 weeks of growth, the artificial blood vessel was taken out, the patency rate was investigated, and after fixing with formalin, critical point drying was performed, and a thrombus membrane formed on the inner surface of the artificial blood vessel was observed with a scanning electron microscope. Was observed and measured. Further, the endothelial cell coverage was observed and measured in the sample 6 weeks after transplantation. Similarly, a pathological tissue specimen was prepared and the state of organizing was observed.
【0058】その結果、比較例に比して、各実施例の人
工血管は、開存率は良好で、形成血栓膜厚みは薄く均一
であった。移植後5分から1時間にかけては、血栓膜の
増加および活性状態が見られたが、1日後には既に血小
板の少ないフィブリン様物質に被われた安定な血栓膜と
なっていた。また、6週後の内皮細胞被覆率は、実施例
で比較例よりも有意に高かった。各実施例の人工血管に
おいては、内皮細胞が被覆した部分は、吻合部から連続
的につながっており、生着した内皮細胞は血流方向に配
向した安定な形態を示した。病理組織標本による観察か
らも、実施例の人工血管の内面はすべて器質化されてお
り、内皮細胞に覆われた部分は平滑筋細胞を含む生体血
管の内膜様の仮性内膜となり、内皮細胞に覆われていな
い部分も器質化された安定な血栓膜となっていた。新鮮
血栓部および人工血管内面がむき出しの部分はなかっ
た。As a result, as compared with the comparative example, the artificial blood vessel of each example had a good patency rate and a thin thrombus film thickness, which was thin and uniform. From 5 minutes to 1 hour after the transplantation, an increase in thrombus membrane and an active state were observed, but one day later, the thrombus membrane was already covered with a fibrin-like substance with few platelets. In addition, the endothelial cell coverage after 6 weeks was significantly higher in Examples than in Comparative Examples. In the artificial blood vessels of the respective examples, the portion coated with endothelial cells was continuously connected from the anastomosis, and the engrafted endothelial cells showed a stable morphology oriented in the blood flow direction. From the observation of the histopathological specimen, the inner surface of the artificial blood vessel of the example was all organized, and the portion covered with endothelial cells became the intimal-like pseudointimal membrane of the living blood vessel containing smooth muscle cells. The part that was not covered by the slab was also an organized and stable thrombus membrane. There was no part where the fresh thrombus and the inner surface of the artificial blood vessel were exposed.
【0059】それに対して、比較例1〜3の人工血管
は、移植後5分〜1日では、形成血栓膜の厚みが不均一
で、移植後1日でも血小板を含む安定しない血栓が部分
的に観察された。また、移植6週後では、閉塞例も見ら
れ、開存例でも、人工血管内面に新鮮血栓部および人工
血管内面がむき出しの部分があった。内皮細胞が被覆し
た部分もあったが、その直下に比較的新しい血栓膜が認
められ、初期に形成した血栓膜の上に何度かの血栓膜が
再形成したと考えられた。比較例1〜3の人工血管で
は、実施例の人工血管で観察された吻合部からの連続性
は観察されず、内皮細胞で被覆部分の中に被覆されない
部分が存在しており、内皮細胞の配向も乱れた部分が被
覆面積の半分を占めた。On the other hand, in the artificial blood vessels of Comparative Examples 1 to 3, the formed thrombus membrane had an uneven thickness 5 minutes to 1 day after the transplantation, and the unstable thrombus containing platelets was partially present even 1 day after the transplantation. Was observed. In addition, 6 weeks after the transplantation, an obstructed case was also seen, and even in the patency case, there was a part where the fresh blood clot and the inner surface of the artificial blood vessel were exposed on the inner surface of the artificial blood vessel. Although there was a portion covered with endothelial cells, a relatively new thrombus membrane was found just below it, and it is considered that several thrombus membranes were re-formed on the thrombus membrane that was initially formed. In the artificial blood vessels of Comparative Examples 1 to 3, the continuity from the anastomotic part observed in the artificial blood vessels of Examples is not observed, and there is a portion not covered with the endothelial cells in the covered portion, The part where the orientation was disturbed occupied half of the coated area.
【0060】比較例4〜5の人工血管では、移植直後か
ら顕著な血栓性が観察され、徐々に開存率が低下した。
特に比較例5の人工血管は、移植後1時間ですべて閉塞
してしまった。比較例4の人工血管も移植6週後にはす
べて閉塞した。以上の実施例、比較例の人工血管の構造
および特性、評価結果を表1にまとめた。In the artificial blood vessels of Comparative Examples 4 to 5, remarkable thrombotic properties were observed immediately after transplantation, and the patency rate gradually decreased.
In particular, the artificial blood vessel of Comparative Example 5 was completely blocked one hour after transplantation. The artificial blood vessel of Comparative Example 4 was also completely blocked 6 weeks after transplantation. Table 1 shows the structures and characteristics of the artificial blood vessels of the above Examples and Comparative Examples, and the evaluation results.
【0061】[0061]
【表1】 [Table 1]
【0062】[0062]
【発明の効果】本発明の人工血管は、PTFE材質によ
る薄い血栓膜を形成する性質に加えて、内腔表面に設け
た微少な凹凸構造によってその形成血栓膜を安定に保持
する性質を合わせ持つ。この2つの性質によって形成さ
れる薄い安定な血栓膜は、人工血管内面の薄く安定な仮
性内膜の形成、特に生体血管と同等の抗血栓性を獲得す
るために必要な内皮細胞膜の形成を促進し、移植後きわ
めて短期間のうちに生体血管様の器質化を完了し、形成
された安定な内膜によって良好な開存率を長期にわたっ
て実現することが可能である。The artificial blood vessel of the present invention has not only the property of forming a thin thrombus membrane made of PTFE material, but also the property of stably holding the formed thrombus membrane due to the minute concavo-convex structure provided on the surface of the lumen. .. The thin and stable thrombus membrane formed by these two properties promotes the formation of a thin and stable pseudointimal membrane on the inner surface of the artificial blood vessel, particularly the formation of the endothelial cell membrane necessary to acquire the antithrombotic property equivalent to that of the living blood vessel. However, it is possible to complete organizing like a living blood vessel within a very short period of time after transplantation and to achieve a good patency rate for a long period of time by the formed stable intimal membrane.
【0063】内径6mm以下の人工血管、特に内径3m
m以下の小口径領域の人工血管においては、大口径と同
じ厚みの血栓膜、仮性内膜であっても血液の流れる内腔
の径の減少率が高くなること、小口径領域では大口径よ
りも血流が遅く、血栓性が高く閉塞しやすいことから、
この薄い仮性内膜が早期に安定に完成することは、長期
開存性を獲得する上で非常に有効である。したがって、
本発明の人工血管は、大中口径領域の閉塞性血管疾患や
動脈瘤などにおける血管代替においても優れた特性を示
すが、内径6mm以下の人工血管、特に内径3mm以下
の、抹消血管や冠状動脈など小口径領域の血管疾患の治
療に使用される人工血管において、特に有効である。An artificial blood vessel with an inner diameter of 6 mm or less, especially an inner diameter of 3 m
In an artificial blood vessel with a small diameter region of m or less, the thrombus membrane having the same thickness as the large diameter or the pseudointimal membrane has a higher reduction rate of the diameter of the lumen through which blood flows. Blood flow is slow, and because it has a high thrombotic property and is easy to occlude,
The early and stable completion of this thin pseudointimal membrane is very effective in achieving long-term patency. Therefore,
The artificial blood vessel of the present invention exhibits excellent properties in vascular replacement in obstructive vascular disease in large and medium diameter areas and aneurysms, but artificial blood vessels with an inner diameter of 6 mm or less, particularly peripheral blood vessels and coronary arteries with an inner diameter of 3 mm or less. It is particularly effective for artificial blood vessels used for the treatment of vascular diseases in the small diameter region.
【図面の簡単な説明】[Brief description of drawings]
【図1】本発明の人工血管の一例を示す模式図である。FIG. 1 is a schematic diagram showing an example of an artificial blood vessel of the present invention.
【図2】図1の点線で囲った部分(A)の断面を拡大し
た模式図である。FIG. 2 is an enlarged schematic view of a section (A) surrounded by a dotted line in FIG.
1 PTFE繊維(フィブリル) 2 結節(ノード) 3 人工血管内腔表面の凹凸構造の凹部 4 人工血管内腔表面の凹凸構造の凸部 5 管状四弗化エチレン樹脂多孔質体(人工血管) 1 PTFE fiber (fibril) 2 Nodule (node) 3 Recessed portion of uneven structure on artificial lumen inner surface 4 Convex portion of uneven structure on artificial blood vessel lumen surface 5 Tubular tetrafluoroethylene resin porous body (artificial blood vessel)
Claims (4)
結節とからなる微細繊維状組織を有する管状四弗化エチ
レン樹脂多孔質体製の人工血管において、少なくともそ
の内腔表面に微細繊維状組織の切断・収縮および/また
は分解・除去された部分により形成された凹凸構造を有
することを特徴とする人工血管。1. An artificial blood vessel made of a tubular tetrafluoroethylene resin porous body having a fine fibrous tissue composed of fibers and nodules connected to each other by the fine fibrous tissue at least on the inner surface of the lumen. An artificial blood vessel characterized by having a concavo-convex structure formed by cut / contracted and / or decomposed / removed portions.
深さ5〜20μm、かつ、管状構造の長軸方向の平均幅
10〜50μmの凹部を有する請求項1記載の人工血
管。2. The artificial blood vessel according to claim 1, wherein the concavo-convex structure formed on the surface of the lumen has a recess having an average depth of 5 to 20 μm and an average width of the tubular structure in the longitudinal direction of 10 to 50 μm.
結節とからなる微細繊維状組織を有する管状四弗化エチ
レン樹脂多孔質体の少なくとも内腔表面をアルカリ金属
化合物の有機溶剤溶液で処理し、微細繊維状組織を分解
した後、分解物を除去して、少なくとも内腔表面に凹凸
構造を形成することを特徴とする人工血管の製造方法。3. A tubular tetrafluoroethylene resin porous body having a fine fibrous structure composed of fibers and nodules connected to each other is treated at least on the inner surface with an organic solvent solution of an alkali metal compound, A method for producing an artificial blood vessel, which comprises decomposing a fine fibrous tissue and then removing the decomposed product to form an uneven structure at least on the surface of the lumen.
くとも内腔表面をメチルリチウム、ナトリウム−ナフタ
レン錯体またはナトリウム−アントラセン錯体の有機溶
剤溶液で処理した後、過酸化水素水または次亜塩素酸ソ
ーダで処理する請求項3記載の人工血管の製造方法。4. A tubular tetrafluoroethylene resin porous body is treated with a solution of methyllithium, sodium-naphthalene complex or sodium-anthracene complex in an organic solvent at least on the inner surface thereof, and then hydrogen peroxide water or hypochlorous acid is added. The method for producing an artificial blood vessel according to claim 3, which is treated with soda.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4076261A JPH05237141A (en) | 1992-02-27 | 1992-02-27 | Artificial blood vessel and its production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4076261A JPH05237141A (en) | 1992-02-27 | 1992-02-27 | Artificial blood vessel and its production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05237141A true JPH05237141A (en) | 1993-09-17 |
Family
ID=13600277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4076261A Pending JPH05237141A (en) | 1992-02-27 | 1992-02-27 | Artificial blood vessel and its production |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05237141A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006022083A1 (en) * | 2004-08-23 | 2006-03-02 | Sumitomo Electric Industries, Ltd. | Method for producing porous resin substrate having hole bored therethrough and porous resin substrate provided with hole having inner wall surface imparted with electroconductivity |
| JP2009538193A (en) * | 2006-05-24 | 2009-11-05 | ボストン サイエンティフィック リミテッド | Micro sintered node ePTFE structure |
| JP2016214210A (en) * | 2015-05-26 | 2016-12-22 | 住友電気工業株式会社 | Cell culture carrier, and cell sheet including the same |
| JP2018145478A (en) * | 2017-03-06 | 2018-09-20 | ストローブ株式会社 | Film deposition method |
| US10950143B2 (en) | 2016-08-31 | 2021-03-16 | Ricoh Company, Ltd. | Hydrogel structure, blood vessel, internal organ model, practice tool for medical procedure, and method of manufacturing the hydrogel structure |
-
1992
- 1992-02-27 JP JP4076261A patent/JPH05237141A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006022083A1 (en) * | 2004-08-23 | 2006-03-02 | Sumitomo Electric Industries, Ltd. | Method for producing porous resin substrate having hole bored therethrough and porous resin substrate provided with hole having inner wall surface imparted with electroconductivity |
| US7807066B2 (en) | 2004-08-23 | 2010-10-05 | Sumitomo Electric Industries, Ltd. | Method of manufacturing a porous resin substrate having perforations and method of making a porous resin substrate including perforations having electrically conductive wall faces |
| JP2009538193A (en) * | 2006-05-24 | 2009-11-05 | ボストン サイエンティフィック リミテッド | Micro sintered node ePTFE structure |
| JP2016214210A (en) * | 2015-05-26 | 2016-12-22 | 住友電気工業株式会社 | Cell culture carrier, and cell sheet including the same |
| US10950143B2 (en) | 2016-08-31 | 2021-03-16 | Ricoh Company, Ltd. | Hydrogel structure, blood vessel, internal organ model, practice tool for medical procedure, and method of manufacturing the hydrogel structure |
| JP2018145478A (en) * | 2017-03-06 | 2018-09-20 | ストローブ株式会社 | Film deposition method |
| US11401604B2 (en) | 2017-03-06 | 2022-08-02 | National University Corporation Okayama University | Film formation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6436135B1 (en) | Prosthetic vascular graft | |
| Doi et al. | Novel compliant and tissue‐permeable microporous polyurethane vascular prosthesis fabricated using an excimer laser ablation technique | |
| US4167045A (en) | Cardiac and vascular prostheses | |
| CN105031735B (en) | A kind of three-layer composite structure small-caliber artificial blood vessel and preparation method thereof | |
| US4863668A (en) | Method of forming fibrin-collagen nerve and body tissue repair material | |
| WO2000072894A1 (en) | Prosthesis for blood vessel | |
| WO2008038424A1 (en) | Artificial blood vessel for small artery using fibroin thread | |
| JPH05237141A (en) | Artificial blood vessel and its production | |
| JPH0242656B2 (en) | ||
| JP3687995B2 (en) | Artificial blood vessel and manufacturing method thereof | |
| White et al. | Preliminary report: Evaluation of tissue ingrowth into experimental Replamineform vascular prostheses | |
| JP2814415B2 (en) | Artificial blood vessel and its manufacturing method | |
| JPS632620B2 (en) | ||
| KR100201874B1 (en) | An artificial organ having a porous and biodegradable character and its manufacturing method | |
| JPH0240341B2 (en) | ||
| JPS62152467A (en) | Method for manufacturing tubular organ prosthesis material | |
| JP3003208B2 (en) | Vascular prostheses and patches | |
| WO1992002195A1 (en) | Artificial blood vessel and production thereof | |
| JPS6037736B2 (en) | Tubular organ prosthetics | |
| JPH0732798B2 (en) | Composite structure tubular organ prosthesis | |
| JPH0262264B2 (en) | ||
| RU2805590C1 (en) | Method for manufacturing small-diameter blood vessel prostheses by electrospinning and a device for its implementation | |
| JPH04300537A (en) | Composite artificial blood vessel | |
| JPS5834137B2 (en) | Composite structure vascular prosthesis and its manufacturing method | |
| Mankodi | Application of textile materials in cardiovascular implants |